Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Cost of Revenue (2016 - 2025)

CorMedix's Cost of Revenue history spans 13 years, with the latest figure at $27.1 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 228.32% year-over-year to $27.1 million; the TTM value through Dec 2025 reached $38.1 million, up 32.42%, while the annual FY2025 figure was $38.1 million, 32.42% up from the prior year.
  • Cost of Revenue for Q4 2025 was $27.1 million at CorMedix, up from $7.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $27.1 million in Q4 2025 and bottomed at -$1.0 million in Q2 2025.
  • The 5-year median for Cost of Revenue is $61339.0 (2021), against an average of $4.1 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 980637.05% in 2023 before it crashed 113.74% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $48007.0 in 2021, then crashed by 99.15% to $406.0 in 2022, then skyrocketed by 801882.02% to $3.3 million in 2023, then skyrocketed by 153.81% to $8.3 million in 2024, then skyrocketed by 228.32% to $27.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Cost of Revenue are $27.1 million (Q4 2025), $7.5 million (Q3 2025), and -$1.0 million (Q2 2025).